CTLA4 and neoplasm: Interestingly, when this triple combination therapy was tried with singular administration of CP (anti-CTLA4 mAb or anti-PD-L1 mAb) no therapeutic efficacy was seen (Supplementary Fig. 2), suggesting that targeting both pathways simultaneously is beneficial in overcoming resistance mechanisms in this aggressive tumor model.